Afferent raises $55m from IPO-focused investors
This article was originally published in Scrip
San Mateo, California-based Afferent Pharmaceuticals will prepare for a Phase III study for lead drug candidate AF-219 and take a second P2X3 antagonist into the clinic with $55m in venture capital from investors that hope the private company will go public fairly soon.
You may also be interested in...
A candidate for chronic cough is one of the assets Merck & Co. will get by buying P2X3 inhibitor specialist Afferent Pharmaceuticals Inc, a US-based biotech focusing on chronic pain therapies caused when certain nerves become hypersensitive.
Roche has partnered with Regeneron and Atea, but the company continues to leverage its long legacy in infectious diseases to identify good treatment options for the novel coronavirus.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.